Although prior studies have demonstrated RTK and downstream PI3K/AKT/mTOR amplifications in DIPG, monotherapy against the PI3K pathway has failed to show a significant tumor response in various malignancies including DIPG and other CNS tumors.7,8,12,13 We have previously shown how combinatorial therapy resulted in increased caspase-dependent apoptosis.10 In this study, two CED injections were used to best approximate our clinical experience, where one or two CED injections are used in patients.5 The gene discussed is AKT1; the disease is neoplasm.